A Trial to Investigate the Safety, Tolerability, and Drug Levels in Blood After Single and Multiple Doses of LEO 32731 in Healthy People
A Trial to Investigate the Safety, Tolerability, and Drug Levels in Blood After Single and Multiple Doses of LEO 32731 in Healthy People
This is a phase 1 trial to evaluate the safety, tolerability, and pharmacokinetics of 4
 different oral formulations of LEO 32731 in healthy subjects. The trial will be conducted in
 3 parts at a single site. Each eligible subject will be enrolled into 1 group only and will
 participate in 3 treatment periods.
Part 1 will evaluate the pharmacokinetics of single doses of 4 test formulations of LEO 32731
 compared with a reference formulation. Part 2 will evaluate the effect of food on the
 pharmacokinetics of selected test formulations of LEO 32731. Part 3 will evaluate the
 tolerability and safety of selected test formulations of LEO 32731 after multiple dosing.

 Based on data from Part 1, up to 3 formulations will be taken forward to Part 2. If none of
 the formulations are considered appropriate to take forward to Part 2, the trial will stop
 after Part 1. Similarly, based on data from Part 2, up to 2 formulations will be taken
 forward to Part 3. If none of the formulations are considered appropriate to take forward to
 Part 3, the trial will stop after Part 2.
Key inclusion criteria:

 -  Age 18 to 65 years, inclusive.

 -  Body mass index of 18.5 to 29.9 kg/m2, inclusive.

 -  In good health, at the discretion of the investigator, as determined by: medical
 history, physical examination, vital sign assessment (specifically, blood pressure
 must be within normal reference range), 12-lead ECG, clinical laboratory evaluations,
 aspartate aminotransferase and alanine aminotransferase not above the upper limit of
 normal (Gilbert's syndrome is not acceptable).

 -  Female subjects of childbearing potential must be willing to use a highly effective
 form of birth control in conjunction with a barrier method of contraception throughout
 the trial and for at least 90 days after final follow-up.

 -  Male subjects with a female partner of childbearing potential must be willing to use a
 highly effective form of birth control in conjunction with male barrier method of
 contraception (i.e. male condom with spermicide) throughout the trial and for at least
 90 days after final follow-up.

 Key exclusion criteria:

 -  Systemic or topical treatment within 14 days prior to first dose administration unless
 in the opinion of the investigator the medication will not interfere with the trial
 procedures or compromise safety.

 -  Any medications, including St. John's wort, known to chronically alter drug absorption
 or elimination processes within 30 days prior to first dose administration.

 -  Subjects who smoke more than an average of 10 cigarettes per day.

 -  History of chronic alcohol or drug abuse within 12 months prior to screening.

 -  Subjects with ≥3 bowel movements per day.

 -  Any disorder which is not stable and could: Affect the safety of the subject
 throughout the trial; Influence the findings of the trial; Impede the subject's
 ability to complete the trial. Examples include but are not limited to cardiovascular,
 GI, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic,
 haematological, immunological, and psychiatric disorders and major physical
 impairment.